The Outcome was intimated within the prescribed timelines under various heads however the same was inadvertently missed under Results Tab, therefore uploading the same.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Pharmalabs reported standalone FY2025-26 revenue of Rs 1,79,755 lakhs, marginally up from Rs 1,77,135 lakhs in FY2024-25. However, net profit declined sharply to Rs 17,620 lakhs from Rs 25,735 lakhs in the prior year, a drop of about 31.5%. Consolidated revenue fell to Rs 1,81,944 lakhs from Rs 2,11,507 lakhs due to Ganesh Polychem becoming a joint venture from April 2025. Finance costs nearly doubled to Rs 4,690 lakhs (from Rs 2,563 lakhs) and foreign exchange losses of Rs 3,321 lakhs emerged due to a derivative contract fair value adjustment. EBITDA margins compressed from 19% to 13%. The Board declared a final dividend of Rs 2 per share and appointed two new senior management personnel. Auditors issued an unmodified opinion with an Emphasis of Matter on the derivative contract restatement.
The significant PAT decline driven by higher finance costs, foreign exchange losses and exceptional labour code provisions will likely weigh on investor sentiment despite the dividend announcement.